Primary Brain Tumors in Adults James D. Battiste, MD, PhD Assistant Professor Department of Neurology The University of Oklahoma Health Sciences Center October 22, 2013, 8:00 AM
OU Neurology
Objectives Define the 4 brain tumor grades and the 3 subtypes of glioma. Explain the current issues in the diagnosis of adult gliomas Report the current ability of molecular markers to make better prognosis for patients Identify the current treatment options for adult gliomas
OU Neurology
Incidence Central Brain Tumor Registry United States (CBTRUS) database 62,930 new cases of malignant and non-malignant brain tumors in 2007 Estimated 21,810 new cases of malignant CNS tumors in 2008, estimated deaths 13,070 Relative risks: 1.38 Men vs Women 3.18 Elderly vs Young adults 1.86 Caucasian vs. African-American Malignant brain tumors (22,070 cases estimated in 2009) account for 1.42% of all primary malignant cancers in the US (American Cancer Society 2009) but account for a disproportionate share of cancer morbidity and mortality (CDC 2008).
OU Neurology
Take Home: per year 60,000+ new brain tumors 22,000+ new malignant brain tumors 200,000+ new brain met’s Brain tumor: Morbidity & Mortality > other cancers
OU Neurology
Definitions Progression Free Survival (PFS) Time to new or progressive symptoms Time to radiographic expansion of tumor
Overall Survival Time to mortality
OU Neurology
Defined based on the Presumed “Cell of Origin”
Glia Neurons Peripheral Nerve Primary Neuro-ectodermal Tumors Ependymal Sellar region/Pituitary Meningeal Lymphocyte OU Neurology
Primary Brain tumors
Distribution of All Primary Brain and CNS Tumors by Histology, CBTRUS 2000-2004
OU Neurology
Gliomas Tumor cell of origin or differentiation sub-type Oligodendroglioma Mixed: Oligoastrocytoma
Grade I, “benign”
Astrocytoma
Pilocytic Astrocytoma
Grade II, Low grade glioma (LGG)
Oligodendroglioma
LGG oligoastrocytoma
Astrocytoma
Grade III, anaplastic
Anaplastic oligodendroglioma
Anaplastic oligodendroglioma
Anaplastic Astrocytoma
Grade IV
GBM with oligodendroglia features
GBM
OU Neurology
Low grade glioma (WHO Grade II) (i.e. astro, oligo or mixed) Risk factors for higher grade: Age > 40, size >6 cm, Astrocytic component Crossing midline Presence of neurologic deficits other than seizures
Median survival decreases from 9.2 years to 0.7 years Prognostic factors for survival in adult patients with cerebral low-grade glioma. Pignatti F, J Clin Oncol. 2002 Apr 15;20(8):2076-84.
OU Neurology
Oligodendroglioma “Fried Egg” perinuclear clearing
Generally, not enhancing.
Calcifications and microbleeds.
Good prognosis: especially with 1p/19q co-deletion and IDH1 or IDH2 mutation Chemosensitive to carmustin, lomustine, or temazolamide
OU Neurology
Oligodendroglioma Low grade (WHO II)
Anaplastic (WHO III)
High cellularity, classic “fried egg” appearance of cells
Highly cellular, mitotic figures, Microvascular prolif, necrosis
Co-deletion of 1p and 19q (>50%) associated with chemosensitivity Mutation in IDH1 or IDH2 also associated with good prognosis
OU Neurology
1p/19q co-deletion Characteristic pathology in oligodendrogliomas Scattered reports in other tumor types
Jenkins R B et al. Cancer Res 2006;66:9852-9861
OU Neurology
Low grade astrocytoma (WHO II) No contrast enhancement on MRI
FLAIR
Post-Contrast
H&E, smear
Median survival: 10-15 years
OU Neurology
Anaplastic Astrocytoma (WHO III) T1 + gad
H&E
Heterogeneous Enhancing mass (70%)
High cellularity Pleomorphism, mitosis
Median survival: 5 years
OU Neurology
Mixed Glioma (Oligoastrocytoma)
Grade for grade – tumors with an “oligo” component do better in terms of overall survival and progression-free survival They generally do not have 1p/19q co-deletion
OU Neurology
Glioblastoma (IV) T1 + gad
H&E
Enhancing mass, cystic components, variable necrosis
Highly cellular, pseudo-palisading necrosis, microvascular prolif.
Median survival: 14 months
OU Neurology
Bio-Markers and Molecular Characterization MGMT methylation DNA repair gene Removes alkyl group from O6 guanine Epigenetic silencing of the MGMT gene by methylation of the promoter
Methylated: Inactive, tumor cell is vulnerable to methylation/alkylation triggering cytotoxicity and apoptosis
Unmethylated: Active to repair and “protect” tumor cell. Nature: Gene regulation: Code of silence Judd C. Rice1 & C. David Allis1
Vorinostat? HDAC inhibitor…
Hegi et al., NEJM 2005
OU Neurology
The Cancer Genome Atlas (TCGA)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Cancer Cell Volume 17, Issue 1 2010 98 - 110
OU Neurology
Glioblastoma (TCGA)
OU Neurology
Sequencing of GBMs led to the discovery of mutations in Isocitrate Dehydrogenase (IDH)
OU Neurology
Yan et al, NEJM 2009
OU Neurology
Probability of Survi
60
IDH mutations: Better overall survival Excellent prognostic marker 40
IDH mutated
IDH wild-type
20
P=0.002
0 0
A
B
40
50
100
80
60
IDH mutated IDH mutated
40 IDH wild-type
20
P=0.002 0 0
IDH wild-type 10
20
IDH mutated IDH mutated
80
60
40
IDH wild-type IDH wild-type
20
P98%